Publicaciones en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (22)

2022

  1. Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients

    Schizophrenia, Vol. 8, Núm. 1

  2. Inflammation biomarkers in suicide attempts and their relation to abuse, global functioning and cognition

    World Journal of Biological Psychiatry, Vol. 23, Núm. 4, pp. 307-317

  3. The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study

    European Neuropsychopharmacology, Vol. 57, pp. 105-117

2021

  1. A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways

    Frontiers in Pharmacology, Vol. 12

2020

  1. Functionality and Neurocognition in Patients With Bipolar Disorder After a Physical-Exercise Program (FINEXT-BD Study): Protocol of a Randomized Interventionist Program

    Frontiers in Psychiatry, Vol. 11

2019

  1. Association between medication adherence and oxidative stress in patients with first-episode mania

    Frontiers in Psychiatry, Vol. 10, Núm. MAR

  2. CIBERSAM: Ten years of collaborative translational research in mental disorders

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 1-8

2018

  1. Ibero-American consensus on low- and no-calorie sweeteners: Safety, nutritional aspects and benefits in food and beverages

    Nutrients, Vol. 10, Núm. 7

  2. Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: Effect of antidepressants

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia

    Neuropharmacology, Vol. 116, pp. 196-207

2016

  1. BDNF and NGF Signalling in Early Phases of Psychosis: Relationship with Inflammation and Response to Antipsychotics after 1 Year

    Schizophrenia Bulletin, Vol. 42, Núm. 1, pp. 142-151

  2. Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia

    Journal of Psychiatry and Neuroscience, Vol. 41, Núm. 3, pp. E46-E55

2015

  1. Discrimination between Alzheimer's disease and late onset bipolar disorder using multivariate analysis

    Frontiers in Aging Neuroscience, Vol. 7, Núm. DEC

2014

  1. Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study

    Schizophrenia Research, Vol. 156, Núm. 1, pp. 23-29

  2. Birth weight, working memory and epigenetic signatures in IGF2 and related genes: A MZ twin study

    PLoS ONE, Vol. 9, Núm. 8

  3. Functional assembly of Kv7.1/Kv7.5 channels with emerging properties on vascular muscle physiology

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 34, Núm. 7, pp. 1522-1530

2012

  1. Antioxidant defense system and family environment in adolescents with family history of psychosis

    BMC Psychiatry, Vol. 12

  2. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes

    Schizophrenia Research, Vol. 137, Núm. 1-3, pp. 66-72

2010

  1. Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine1A receptor-dependent mechanisms

    Molecular Pharmacology, Vol. 77, Núm. 3, pp. 424-434